DECEMBER 2021

STUDY REVEALS POTENTIAL THERAPEUTIC TARGET FOR GENETIC LIVER DISEASE

Featuring: Deyu Fang, PhD

Northwestern Medicine investigators have discovered the molecular mechanisms underlying a rare genetic mutation that increases the risk of severe liver disease, according to findings published in Molecular Cell.

The study, led by Deyu Fang, PhD, the Hosmer Allen Johnson Professor of Pathology, may reveal potential therapeutic targets for treating the disease.

Alpha-1 antitrypsin (AAT) deficiency is a rare genetic mutation that can increase the risk of developing several diseases, including severe liver disease. One in 3,500 people in the U.S. are diagnosed with the genetic disorder annually.

The AAT protein is made by the liver and moves into bloodstream to protect the liver and other organs from infection. AAT deficiency, however, can cause low levels of AAT in the bloodstream and a build-up of the protein in the liver, which can be life-threatening.

AAT deficiency is caused by a mutation in the serine protease inhibitor 1A (SERPINA1) gene, which produces AAT. On a molecular scale, the mutation results in toxic unfolded proteins that accumulate within the endoplasmic reticulum of hepatocytes — specialized liver cells — and triggers an unfolded protein response for cell stress adaption.

The unfolded protein response is essential to restore the cell’s normal function by stopping protein translation, to degrade misfolded proteins and to activate beneficial cell signaling pathways. Failure of the unfolded protein response, however, induces apoptosis, or cell death, as well as damage to surrounding tissue or organs — in this case, the liver.

The molecular mechanisms that determine how this unfolded protein response selects stress adaption over apoptosis have remained unknown.

In the current study, Fang and colleagues used immunofluorescence to study liver cell lines from mouse models of AAT-induced liver disease.

They found that the accumulation of unfolded proteins upregulated the expression of the metabolic enzyme N6-adenosine-methyltransferase-14, or METTL14, in the mouse models. METTL14 also suppressed C/EBP-homologous (CHOP) protein-induced apoptosis for endoplasmic reticulum stress adaption.

“Mice with liver specific METTL14 deletion are highly susceptible to both acute pharmacological and AAT deficiency-induced endoplasmic reticulum proteotoxic stress and liver injury,” Fang said.

The investigators then crossed METTL14 knockout mouse models with control mouse models of AAT-induced liver disease and found that the knockout mice models survived for only 14 weeks. This suggests that the deletion of the CHOP protein protected the METTL14 knockout mice from proteotoxic liver damage, according to the authors.

Juncheng Wei, PhD, research assistant professor of Pathology in the Division of Research, was lead author of the study. Co-authors include Shana Gregory, a sixth-year student in the Driskill Graduate Program in Life Sciences (DGP), Samuel Weinberg, a third-year resident in the Department of Pathology, and Richard Green, MD, ’89 GME, professor of Medicine in the Division of Gastroenterology and Hepatology.

Green and Fang are members of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University

This work was supported by the National Institutes of Health grants HD104904, CA257520, CA232347, DK120330, DK126908, R35ES031575, R01DK093807, DK121997 and a grant from the Alpha-1 Foundation.

This article was originally published in the Feinberg School of Medicine News Center on December 31, 2021.